XRP News: Vaultro Finance Unveils Its Fund Protocol Dashboard on XRP Ledger – Join $VLT Presale Now!
By GlobeNewswire Published on May 16, 2025, 23:00 IST
SINGAPORE, May 16, 2025 (GLOBE NEWSWIRE) — A new chapter in decentralized finance begins today as Vaultro Finance, the first index fund protocol on the XRP Ledger, officially unveils its user dashboard — now live and available for public access.
PARTICIPATE IN $VLT PRESALE NOW
The dashboard reveal, announced via Vaultro's official Medium article , marks a major milestone in making structured, non-custodial investing accessible to everyone.
For the first time on XRPL, users can create, manage, and invest in tokenized index funds that track high-performance sectors like AI tokens, stablecoins, DeFi assets, and native XRP Ledger tokens — all from a streamlined, intuitive interface.
Why It Matters: Real Utility. Real Decentralization.
The Vaultro Finance dashboard is designed for simplicity and power — no central parties, no custodians. Just users and the protocol, operating on XRP Ledger technology including Hooks and Escrow.
With this launch, Vaultro Finance activates the full functionality of its native token, $VLT , which now powers: Custom fund creation
Governance voting
Platform staking rewards
Reduced minting and rebalancing fees
PARTICIPATE IN $VLT PRESALE NOW
$VLT is no longer just a future utility token — it's the key to the protocol's core operations starting today.
Presale Momentum Builds
With over 25% of the softcap already raised, the ongoing $VLT presale is rapidly gaining attention. Vaultro has confirmed the token will list at 30% higher than the current presale rate — giving early participants a strong financial advantage.
The Interface Is Live. The Token Is Active. The Future Is On-Chain.
Vaultro Finance is building the S&P 500 of crypto — decentralized, transparent, and powered by the XRP Ledger.
For more details on Vaultro Finance and the $VLT presale visit;
Website
Join $VLT Presale
X fka Twitter
Telegram Community
Whitepaper
Blog Channel
Contact:Lee Wang
[email protected]
Disclaimer: This is a paid post and is provided by Vaultro Finance. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice.
Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed.
Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.
Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a9c6b5c7-7722-4ee3-b395-7c83d87dca55
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
XPENG Announces New G6 and G9 Ultra Smart SUVs for Europe
Redefining Performance, Design, and Intelligent Technology for the Next Generation of Electric Vehicles. Powered by Industry-Leading Powertrain Technology: 5C Supercharging Battery and 800V High-voltage SiC Platform across all trims. Charging Speed 12 minutes 10-80% SOC placing it at the forefront of the EV revolution. Smart Comfort Meets All-New Interior and Cockpit Upgrades. Expressive New Colors Inside and Out, adding individuality and Appeal. AMSTERDAM, June 12, 2025 (GLOBE NEWSWIRE) -- XPENG, a leading global smart electric vehicle (EV) manufacturer driven by innovation and advanced AI technology, is proud to unveil the new versions of its Ultra Smart Coupe SUV XPENG G6 and Ultra Smart Premium SUV XPENG G9 for the European market. Both models have been upgraded inside and out and feature XPENG's next-gen full-domain 800V high-voltage SiC platform alongside a 5C supercharging battery. This enables ultra-fast charging up to 525 kW for the new XPENG G9 and 451kW for the new XPENG G6, leading in their class. The new XPENG G6, featuring a complete overhaul and a new color Stellar Purple, will be on static display at Le Mans Village in France starting today. European customers can now register their interest for both models via XPENG's official websites in the Netherlands, Belux, Norway, Denmark, Sweden, Germany, and France. Order will open from XPENG G6 and G9 The Heart of Innovation: The Supercharging Battery Upgraded from 3C to 5C At the core of the new XPENG G6 and G9 is an industry-first upgrade to 5C lithium iron phosphate (LFP) batteries for all trims. This next-gen battery technology offers a safer, more eco-friendly solution by eliminateing the need for resource-intensive and costly minerals such as cobalt and nickel, making the version more sustainable without compromising performance. Both models are equipped with XPENG's industry-leading powertrain technology, including the 5C Supercharging Battery and a full-domain 800V high-voltage SiC platform, available across all trims. The result is exceptional charging speed with a 10-80% State of Charge (SOC) achieved in just 12 minutes, setting new benchmarks. XPENG continues to lead in intelligent driving technology. The new XPENG G6 and G9 features a full upgraded intelligent driving suite, including a MicroFiber capacitance steering wheel, advanced driving chip and single-pixel Lofic architecture for accurate, clearer and longer-range perception for enhanced safety and control. Complementing the driving experience is an upgraded cockpit powered by a high-performance cockpit chip and support for Apple CarPlay & Android Auto as standard, ensuring a smarter, smoother and more joyful 800V High-voltage SiC Platform Revolutionary Design Enhancements The new XPENG G6 is as much about style as it is about substance. The exterior is defined by the all-new 1942 mm full-width Starlight Wing LED light bar, integrated turn signals, and a redesigned rear diffuser for a cleaner finish. The new XPENG G6 Stellar Purple features a low-saturation neutral purple tone with metallic flakes infused into the paint, creating a gradient effect shifting from deep purple to light purple under changing light. Its matte metallic finish glimmers subtly like starlight in the sun, blending a sense of mystery with technology. When paired with the new XPENG G6's streamlined coupe-SUV body, it exudes both elegance and sporty dynamism, setting a benchmark for color aesthetics in the smart mobility XPENG G6 The new XPENG G9 Black Edition delivers an equality captivating presence, dressed in a deep midnight black paint paired with blackened wheels, logos, and fender decorations. The fiery orange brake calipers create a striking visual contrast, adding a mysterious yet sharp XPENG G9 Inside, the new XPENG G6 boasts a completely re-imagined interior that focuses on premium materials, immersive technology, and comfort. The new Super Star-Ring Interior Design has transformed 60% of the cabin, introducing a sleek new dashboard, ambient lighting, and a new capacitive steering wheel. Premium materials and immersive design define the cabin with refined color themes - Dark Gray and Light Gray - enhancing the ultra-modern ambiance. Both the new XPENG G6 and G9 have received significant upgrades in comfort and smart functionality. New XPENG G6: Front seats feature a massage function with lumbar support, delivering refined comfort for both driver and passenger. New XPENG G9: A luxury comfort upgrade featuring an ultra-large three-layer heat-insulating panoramic sunroof, luxurious comfort seats with 10-point XPENG G6 InteriorNew XPENG G9 Interior About XPENG Founded in 2014, XPENG is a leading Chinese AI mobility company that designs, develops, manufactures, and markets intelligent electric vehicles, catering to a growing base of tech-savvy consumers. With the rapid advancement of AI, XPENG aspires to become a global leader in AI mobility, with a mission to lead the intelligent electric vehicle revolution through cutting-edge technology, shaping the future of mobility. To enhance the customer experience, XPENG in-house develops its advanced driver assistance technology (ADAS) and intelligent in-car operating system, along with core vehicle systems such as powertrain and electrical/electronic architecture (EEA). Headquartered in Guangzhou, China, XPENG also operates key offices in Beijing, Shanghai, Silicon Valley, and Amsterdam. Its intelligent electric vehicles are mainly produced at its plants in Zhaoqing and Guangzhou, Guangdong Province. XPENG is listed on the New York Stock Exchange (NYSE: XPEV) and the Hong Kong Stock Exchange (HKEX: 9868). For more information, visit Contacts: For Media Enquiries: XPENG PR Department Email: pr@ Photos accompanying this announcement are available at in to access your portfolio
Forbes
35 minutes ago
- Forbes
U.S. Futures Drop As Trump Says He'll Set Unilateral Tariffs In 2 Weeks
U.S. stock futures slumped early on Thursday—with the Dow index dropping by more than 200 points—after President Donald Trump said his administration will soon send letters to other countries unilaterally outlining the tariff rates that will be imposed on them. U.S. President Donald Trump speaks to the media during a guided tour of the John F. Kennedy Center ... More for the Performing Arts. While attending a show at the Kennedy Center on Wednesday evening, Trump was asked about extending the ongoing 90-day tariff pause—which will expire on July 9—and said: 'I would, but I don't think we're going to have that necessity.' The president said the U.S. was negotiating with 15 countries, including Japan and South Korea. Trump then noted that the U.S. has around '150 plus' trading partners and 'at a certain point, we're just going to send letters out…saying this is the deal, you can take it or leave it.' 'We're going to be sending letters out in about a week and a half, two weeks, to countries, telling them what the deal is,' he added. The president touted the proposed agreement with China as a 'great deal,' adding, 'We're very happy with it, we have everything we need.' U.S. stock futures slumped in premarket trading early Thursday, with the benchmark S&P 500 slipping by 0.4% to 6,004 points. The Dow Futures index was the worst hit, dropping by 0.5% to 42,684 points, while the tech-focused Nasdaq Futures fell 0.4% to 21,799 points.
Yahoo
39 minutes ago
- Yahoo
PCR (qPCR, dPCR, Singleplex, Multiplex) Market Research Report 2025-2030 with Situation Analysis, Executives and Marketing Guide, & Investment Analysts and Management Consultants Guide
Explore the evolving PCR technology landscape with our comprehensive report. Discover market trends, including Singleplex and Multiplex testing, and the impact of digital PCR. Uncover investment opportunities in Point of Care Testing and Molecular Diagnostics. Gain insights with five-year forecasts and expert analysis. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "PCR Markets: Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place Forecasting and Analysis" has been added to offering. This report provides comprehensive insights into how this convergence will shape future market dynamics, presenting critical information for industry stakeholders. The global landscape of disease diagnosis is undergoing a significant transformation, with PCR technology at its forefront. While the pandemic elevated PCR to a dominant position, ushering in a digital revolution within the sector, new markets and technologies are now emerging that may redefine diagnostics. This transition presents both opportunities and challenges for stakeholders. A newly released report offers an in-depth analysis of the market, featuring a five-year forecast that is uniquely segmented into Singleplex and Multiplex testing markets. PCR, which has showcased remarkable adaptability, gained widespread recognition as an essential tool in diagnostics. The advent of digital PCR further promises to enhance its efficacy, offering reduced costs and improved patient outcomes. Moreover, digital PCR stands as a powerful contender in combating Anti Microbial Resistance. For professionals seeking to leverage this data, the report is an indispensable resource that can transform executives into industry experts. It enables informed investment decisions and accurate company valuations, backed by the most current data available. With its detailed five-year market forecasts, the report equips organizations with the tools needed to strategically navigate this evolving landscape. In a market driven by innovation, understanding the nuances of these emerging technologies and their implications is crucial. This report encapsulates the trends, challenges, and opportunities that define the future of PCR technologies and diagnostics. Stay ahead of the curve by accessing the latest findings that will keep PCR at the core of disease detection and management globally. Discover how emerging diagnostics technology and market innovations are reshaping the competitive landscape. Access the full report today to explore untapped potential and prepare for the future of healthcare. Key Topics Covered: 1 Market Guides1.1 Situation Analysis1.2 Guide for Executives and Marketing Staff1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition2.1 What are PCR Technologies?2.2 PCR and Syndromic Testing2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry2.5.1 Global Healthcare Spending2.5.2 Spending on Diagnostics2.5.3 Important Role of Insurance for Diagnostics 3 PCR - Guide to PCR Technologies3.1 Concepts3.1.1 Method3.2 Applications3.2.1 Finding Specific DNA3.2.2 Measuring DNA3.2.3 Medical and Diagnostic Applications3.2.3.1 Carrier, prenatal and tissue typing3.2.3.2 Cancer Diagnosis and Management3.2.3.3 Infectious Disease - New Levels of Accuracy and Sensitivity3.2.3.4 Forensic Applications3.2.3.5 Science and Research3.3 PCR - Advantages and Disadvantages3.4 Different Types of PCR3.4.1 Simple Changes3.4.1.1 Multiplex-PCR3.4.1.2 VNTR PCR3.4.1.3 Asymmetric PCR3.4.1.4 Long PCR3.4.1.5 Nested PCR3.4.1.6 Quantitative PCR3.4.1.7 Hot-start PCR3.4.1.8 Touchdown PCR3.4.1.9 Assembly PCR3.4.1.10 Colony PCR3.4.1.11 Suicide PCR3.4.1.12 Cold PCR3.4.2 Digital PCR3.4.2.1 Droplet Digital PCR3.4.2.2 Comparison between dPCR and Real-Time PCR (qPCR)3.4.2.3 Digital PCR in Use3.4.2.4 Digital PCR Commercial History3.4.3 Isothermal PCR 4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body 5 Market Trends5.1 Factors Driving Growth5.1.1 A New Standard5.1.2 Down the Curve We Go5.1.3 Multiplexing5.1.4 Syndromic Diagnostics Looks Unstoppable5.1.5 The Genetic Blizzard5.2 Factors Limiting Growth5.2.1 The Cost Curve5.2.2 The Other Guys5.2.3 Systemic Roadblocks5.3 Diagnostic Technology Development5.3.1 The Instrumentation Curve5.3.2 Shifting Role of Diagnostics5.3.3 Diagnostics Moves Out of the Hospital5.3.4 Disruption Looms5.3.5 The Next Five Years 6 PCR Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Seegene, Microsoft Collaborate for MDx Development6.3 QuidelOrtho Expanding Savanna Test Menu6.4 Binx Health Refocuses on POC STI Testing6.5 Qiagen, Myriad Genetics Partner to Develop Cancer Dx6.6 VedaBio Detecting Nucleic Acid With CRISPR6.7 Evvy Launches Add-on STI Screen6.8 ChromaCode Shifts to Oncology with dPCR Lung Cancer Test6.9 Multiplex Meningitis/Encephalitis Panel Market Expanding6.10 Sensible Dx to Launch 10-Minute POC PCR System6.11 ReadyGo Dx Plans to Make MDx Testing Easy6.12 Transformative Biotech Acquires Summit Biolabs' PCR Tech6.13 Visby Medical POC STI Multiplex Test Cleared6.14 Sherlock Biosciences Buys Sense Biodetection6.15 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx6.16 HealthTrackRx Investing in Rapid Turnaround Times6.17 LEX Dx Developing Ultra-Fast Low-Cost PCR6.18 Next-Gen Dx Technologies Face Uncertain Future6.19 Rover Dx Developing All-Optical Rapid POC qPCR Platform6.20 ProtonDx Plans Rapid Molecular Dx Instrument6.21 Innova Medical Group Licenses MDx Tech6.22 MicroGEM to Grow Market for 30-Minute RT-PCR System6.23 Precipio Receives CE-IVD Mark for Cancer Panels6.24 Siemens Healthineers to Develop Next-Gen MDx Platform6.25 New York State Approves Enzo Biochem HPV Molecular Test6.26 Grip Molecular Developing Biosensor Panel to Detect Respiratory Infections6.27 Co-Diagnostics Seeks EUA for At-Home PCR Diagnostic System6.28 Chelex-Based Protocol to Reduce Cost, Time for PCR Testing6.29 Finnish Firms to Form Point-of-Care Testing Firm6.30 Visby Medical Scales Up Handheld PCR Test for STIs6.31 DnaNudge Raises $60M6.32 Roche Reports Diagnostics Revenue Up 51 Percent6.33 BforCure Preparing Multiple ID Panels for PoC qPCR Platform6.34 Enzo Biochem, CLX Health Partner for C19 Testing for Travel6.35 Bio Molecular Systems Gets Approval for Portable PCR Cycler6.36 Roche Acquires GenMark6.37 Handheld qPCR Devices Close to Commercialization6.38 Nuclein Closes $14M in Funding6.39 WuXi Diagnostics Closes $150M Series B Financing Round6.40 Visby Medical to develop rapid Flu-COVID PCR test6.41 Thermo Fisher to Acquire Mesa Biotech 7 Profiles of Key PCR Companies7.1 Abbott Laboratories7.2 Accelerate Diagnostics7.3 Ador Diagnostics7.4 ADT Biotech7.5 Agilent7.6 Akonni Biosystems7.7 Altona Diagnostics7.8 Alveo Technologies7.9 Amoy Diagnostics Co., Ltd.7.10 Anatolia Geneworks7.11 Applied BioCode7.12 Applied DNA Sciences7.13 Aurora Biomed7.14 Aus Diagnostics7.15 AVIVA Systems Biology7.16 Beckman Coulter Diagnostics (Danaher)7.17 Becton, Dickinson and Company7.18 Binx Health7.19 Biocartis7.20 bioMerieux Diagnostics7.21 Bioneer Corporation7.22 Bio-Rad Laboratories, Inc7.23 Bosch Healthcare Solutions GmbH7.24 Bruker7.25 Caris Molecular Diagnostics7.26 Cepheid (Danaher)7.27 Credo Diagnostics Biomedical7.28 CTK Biotech7.29 Cue Health7.30 Curetis (OpGen)7.31 Diagenode Diagnostics (Hologic)7.32 Diasorin S.p.A.7.33 Eiken Chemical7.34 Enzo Biochem7.35 Eurofins Scientific7.36 Fluxergy7.37 Fujirebio7.38 Genetic Signatures7.39 GenMark Dx (Roche)7.40 Greiner Bio-One7.41 Hologic7.42 Immunexpress7.43 Inflammatix7.44 Invetech7.45 J&J Innovative Medicine7.46 Karius7.47 LumiraDx7.48 Maxim Biomedical7.49 Meridian Bioscience7.50 Millipore Sigma7.51 Molbio Diagnostics7.52 Nanomix7.53 NGeneBio7.54 Novacyt7.55 Nuclein7.56 Operon7.57 Panagene7.58 Precipio7.59 Primerdesign (Novacyt)7.60 Promega7.61 Prominex7.62 Qiagen7.63 QuantuMDx7.64 QuidelOrtho7.65 Randox Toxicology7.66 R-Biopharm AG7.67 Revvity7.68 Roche Diagnostics7.69 Scope Fluidics7.70 SD Biosensor7.71 Seegene7.72 Siemens Healthineers7.73 SkylineDx7.74 Sona Nanotech7.75 SpeeDx7.76 Standard BioTools7.77 Stilla Technologies7.78 Streamline Scientific7.79 T2 Biosystems7.80 Thermo Fisher Scientific7.81 Uniogen7.82 Vela Diagnostics7.83 Veramarx7.84 Veredus Laboratories7.85 Vircell7.86 Visby Medical7.87 XCR Diagnostics7.88 YD Diagnostics7.89 Zhejiang Orient Gene Biotech 8 The Global PCR Markets8.1 PCR - Global Market Overview by Country8.2 Global Market by Application - Overview8.3 Global Market by Technology - Overview8.4 Global Market by Product - Overview8.5 Global Market by Place - Overview 9 Global PCR Markets - By Application9.1 PCR Clinical Multiplex9.2 PCR Clinical Singleplex9.3 PCR Research 10 Global PCR Markets - By Technology10.1 qPCR10.2 dPCR 11 Global PCR Markets - By Product11.1 PCR Instruments11.2 PCR Nucleic Acid Extraction11.3 PCR Consumables11.4 PCR Services 12 Global PCR Markets - By Place12.1 PCR Clinical Laboratory12.2 PCR Point of Care12.3 PCR Commercial12.4 PCR Pharmaceutical 13 Appendices13.1 Growth of Approved IVD Test Menu13.2 Growth of Approved Average IVD Test Fee13.3 The Most Used IVD Assays13.4 The Highest Grossing Assays13.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
